プレシジョンメディシン市場：タイプ別（阻害剤、モノクローナル抗体、細胞・遺伝子治療、抗ウイルス剤、抗レトロウイルス剤）、適応症別（腫瘍学、希少疾患、血液学、感染症）、エンドユーザー別（病院・クリニック、在宅医療）、地域別 - 2028年までの世界予測

Precision Medicine Market by Type (Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral), Indication (Oncology, Rare diseases, Hematology, Infectious), End user (Hospitals & Clinics, Home care) & Region - Global Forecast to 2028

精密医療市場は、予測期間中に年平均成長率11.5%で、2023年の291億米ドルから2028年には502億米ドルに達すると予測されている。精密医療市場の成長を促進する主な要因としては、ゲノム研究に関連するイニシアチブ... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年9月6日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	234	239	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

精密医療市場は、予測期間中に年平均成長率11.5%で、2023年の291億米ドルから2028年には502億米ドルに達すると予測されている。精密医療市場の成長を促進する主な要因としては、ゲノム研究に関連するイニシアチブの拡大、個別化治療薬に対する規制当局の承認数の増加などが挙げられる。さらに、細胞治療や遺伝子治療に対する需要の高まりは、この市場の機会領域となっている。
精密医療市場は、タイプ、適応症、エンドユーザー、地域によって区分されている。
"タイプ別では、モノクローナル抗体セグメントが精密医療市場で第2位のシェアを占める"
タイプ別では、精密医療市場は阻害薬、モノクローナル、細胞・遺伝子治療、抗ウイルス・抗レトロウイルス薬、その他の治療製品に分類される。2022年には、モノクローナル抗体が従来の医薬品よりも優れているなどの要因により、モノクローナル抗体が最も高い成長率を占めた。これらの利点により、臨床パイプラインの焦点はモノクローナル抗体にシフトしている。
"エンドユーザー別では、病院・クリニック分野が精密医療市場で最大のシェアを占める"
エンドユーザーに基づき、精密医療市場は病院・診療所と在宅医療環境に区分される。2022年には、病院・診療所セグメントが精密医療市場で最大のシェアを占めた。この市場セグメントの成長は、病院での遺伝子検査、診断、カウンセリングなどのサービスが利用できることに起因している。その上、病院は、精密医療を選択する患者のために用意された治療製品を容易に入手することができる。

「北米：精密医療市場で最大のシェア
北米は精密医療市場で最大のシェアを占めている。北米地域の大きなシェアは、精密医療を提供する医療環境における技術的に高度なインフラの存在や、先進的な治療薬への容易なアクセスなどの主な要因によるものである。加えて、この地域には確立された医療制度があり、この市場の成長をさらに後押ししている。
「欧州：精密医療市場で最も急成長している地域"
欧州の精密医療市場は、予測期間中に最も高いCAGRで成長すると予測されている。これは、同市場における主要プレイヤーの存在と精密医療の進歩に向けたイニシアチブの高まりを含む主要要因の1つに起因している。これらのプレイヤーの例としては、F. Hoffmann-La Roche Ltd. (スイス)、Novartis AG.(スイス）、Novartis AG（スイス）、AstraZeneca（英国）、GlaxoSmithKline plc（英国）などが挙げられる。
本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別回答者別：供給側70％、需要側30
- 役職別マネージャー45％、ディレクター30％、エグゼクティブ25
- 国別北米25％、欧州25％、アジア太平洋40％、中南米5％、中東2.5％、アフリカ2.5

著名プレイヤー
- ホフマン・ラ・ロシュ社（スイス(ホフマン・ラ・ロシュ社（スイス）
- ノバルティスAG（スイス）
- ファイザー（米国）
- ブリストル・マイヤーズスクイブ（米国）
- アストラゼネカ（英国）
- ギリアド・サイエンシズ（米）
- アッヴィ社（米国）
- イーライリリー・アンド・カンパニー（米）
- グラクソ・スミスクライン（英）
- サノフィ（仏）
- ジョンソン・エンド・ジョンソン（米国）
- メルクKGaA（ドイツ）
- アムジェン（米）
- 武田薬品工業（日本）
- リジェネロン社（米国）
- サレプタ・セラピューティクス社（米国）
- ブルーバードバイオ（米）
- イムノコアホールディングス（英）
- ブループリントメディシンズコーポレーション（米）
- バーテックス・ファーマシューティカルズ・インコーポレイテッド（米）
- ホライゾン・セラピューティクス Plc（アイルランド）
- アルナイラム・ファーマシューティカルズ（米国）
- ライゲル・ファーマシューティカルズ（米国）
- 大鵬薬品工業（日本(大鵬薬品工業（日本）
- シーゲン社（米国）
調査範囲
この調査レポートは、精密医療市場の詳細な姿を提供しています。種類、適応症、エンドユーザー、地域（北米、欧州、アジア太平洋、中南米、中東、アフリカ）など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィール、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、精密医療市場およびそのセグメントの売上高に最も近い概算値を提供することで、市場リーダー／新規参入者を支援します。また、利害関係者が競争状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、利害関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、動向、機会、および課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します。
- 精密医療市場の成長に影響を与える主要促進要因（ゲノム研究、遺伝子検査、コンパニオン診断の成長）、機会（細胞・遺伝子治療の需要）、抑制要因（予算の制約）、課題（精密医療の採用に伴う課題）の分析
- 製品開発/イノベーション：精密医療市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報-本レポートでは、様々な地域における精密医療市場を分析しています。
- 市場の多様化：精密医療市場における新製品やサービス、未開拓の地域、最近の開発、投資に関する情報を網羅的に提供します。
- 競合評価：F.ホフマン・ラ・ロシュ社（スイス）、ノバルティス社（スイス）など主要企業の市場シェア、成長戦略、製品ラインアップを詳細に評価。(スイス）、Novartis AG（スイス）、Bristol Myers Squibb（米国）、Gilead Sciences, Inc.（米国）、AstraZeneca（英国）、Pfizer Inc.（米国）、AbbVie Inc.(米国）、イーライリリー・アンド・カンパニー（米国）、グラクソ・スミスクライン・ピーエルシー（英国）、サノフィ（フランス）、ジョンソン・エンド・ジョンソン（米国）、メルクKGaA（ドイツ）、アムジェン（米国）、武田薬品工業（日本）などが精密医療市場に参入している。

ページTOPに戻る

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS AND EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED 30
FIGURE 1 PRECISION MEDICINE MARKET SEGMENTATION 30
1.3.2 YEARS CONSIDERED 30
1.4 CURRENCY CONSIDERED 31
1.5 LIMITATIONS 31
1.6 STAKEHOLDERS 31
1.6.1 RECESSION IMPACT 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 2 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.2 PRIMARY DATA 35
FIGURE 3 PRECISION MEDICINE MARKET: BREAKDOWN OF PRIMARIES 35
2.2 MARKET SIZE ESTIMATION 36
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 36
FIGURE 5 MARKET SIZE ESTIMATION FOR PRECISION MEDICINE: REVENUE SHARE ANALYSIS 37
2.2.1 INSIGHTS FROM PRIMARIES 38
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 38
2.2.2 SEGMENT ASSESSMENT (BY TYPE, INDICATION, AND END USER) 38
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 38
2.3 GROWTH FORECAST 39
FIGURE 8 PRECISION MEDICINE MARKET: CAGR PROJECTIONS 40
FIGURE 9 PRECISION MEDICINE MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 41
FIGURE 10 DATA TRIANGULATION METHODOLOGY 41
2.5 RESEARCH ASSUMPTIONS 42
2.6 RISK ANALYSIS 42
2.7 RECESSION IMPACT ANALYSIS 42
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 42

3 EXECUTIVE SUMMARY 44
FIGURE 11 PRECISION MEDICINE MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 44
FIGURE 12 PRECISION MEDICINE MARKET, BY INDICATION, 2023 VS. 2028 45
FIGURE 13 PRECISION MEDICINE MARKET, BY END USER, 2023 VS. 2028 45
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET 46
4 PREMIUM INSIGHTS 47
4.1 PRECISION MEDICINE MARKET OVERVIEW 47
FIGURE 15 INCREASING REGULATORY APPROVALS FOR PRECISION MEDICINES TO DRIVE MARKET 47
4.2 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE AND COUNTRY 48
FIGURE 16 INHIBITOR DRUGS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA (2022) 48
4.3 PRECISION MEDICINE MARKET, BY INDICATION 48
FIGURE 17 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 48
4.4 PRECISION MEDICINE MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 49
FIGURE 18 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 19 PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2.1 DRIVERS 51
5.2.1.1 Growing focus on genomic research 51
TABLE 2 INITIATIVES IN GENOMIC RESEARCH AND PRECISION MEDICINE 51
5.2.1.2 Growth in genetic testing and companion diagnostics 52
5.2.1.3 Increasing regulatory approvals for personalized therapeutics 52
5.2.2 RESTRAINTS 53
5.2.2.1 High costs of therapeutic development 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Rising demand for cell and gene therapies 53
5.2.4 CHALLENGES 53
5.2.4.1 Challenges associated with adoption of precision medicine 53
5.3 PORTER’S FIVE FORCES ANALYSIS 54
TABLE 3 PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 54
5.3.1 THREAT OF NEW ENTRANTS 54
5.3.2 THREAT OF SUBSTITUTES 54
5.3.3 BARGAINING POWER OF SUPPLIERS 54
5.3.4 BARGAINING POWER OF BUYERS 54
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 55
5.4 TECHNOLOGY ANALYSIS 55

5.5 VALUE CHAIN ANALYSIS 55
FIGURE 20 PRECISION MEDICINE MARKET: VALUE CHAIN 55
5.5.1 RESEARCH & DEVELOPMENT 56
5.5.2 MANUFACTURING 56
5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES ACTIVITIES 56
5.6 ECOSYSTEM ANALYSIS 56
FIGURE 21 PRECISION MEDICINE MARKET: ECOSYSTEM MAP 56
5.7 PATENT ANALYSIS 57
FIGURE 22 PATENT APPLICATIONS FOR PRECISION MEDICINE THERAPEUTIC PRODUCTS (JANUARY 2012–JULY 2023) 57
TABLE 4 PRECISION MEDICINE MARKET: INDICATIVE LIST OF PATENTS 57
5.8 PIPELINE ANALYSIS 58
TABLE 5 PRECISION MEDICINE THERAPEUTICS IN CLINICAL PIPELINE 58
5.9 SUPPLY CHAIN ANALYSIS 64
5.9.1 PROMINENT COMPANIES 64
5.9.2 SMALL AND MEDIUM-SIZED ENTERPRISES 64
5.9.3 END USERS 64
5.9.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES 64
5.9.5 REGULATORY BODIES 64
FIGURE 23 PRECISION MEDICINE THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS 65
TABLE 6 PRECISION MEDICINE MARKET: SUPPLY CHAIN ECOSYSTEM 65
5.10 REGULATORY ANALYSIS 66
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
5.11 PRICING ANALYSIS 68
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS 68
TABLE 11 AVERAGE SELLING PRICE OF PRECISION MEDICINE THERAPEUTICS 68
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69
5.13 KEY CONFERENCES AND EVENTS 69
TABLE 12 PRECISION MEDICINE MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023–2024) 69
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 70
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 70
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRECISION MEDICINE THERAPEUTICS IN HOSPITALS AND CLINICS 70
5.14.2 BUYING CRITERIA FOR PRECISION MEDICINE MARKET 71
FIGURE 25 KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS 71
6 PRECISION MEDICINE MARKET, BY TYPE 72
6.1 INTRODUCTION 73
TABLE 13 PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 73
6.2 INHIBITOR DRUGS 73
6.2.1 ADVANTAGES OF HIGH ACCURACY AND AFFORDABILITY TO DRIVE MARKET 73
TABLE 14 APPROVED INHIBITOR DRUGS IN PRECISION MEDICINE MARKET (2022) 74
TABLE 15 PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION, 2021–2028 (USD MILLION) 74
TABLE 16 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 17 EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 18 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 75
6.3 MONOCLONAL ANTIBODIES 76
6.3.1 HIGH SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET 76
TABLE 19 PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 76
TABLE 20 NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 21 EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 22 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 77
6.4 CELL AND GENE THERAPY 78
6.4.1 WIDE APPLICATIONS IN ONCOLOGY THERAPEUTICS TO FUEL MARKET 78
TABLE 23 PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 78
TABLE 24 NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 25 EUROPE: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 26 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.5 ANTIVIRAL AND ANTIRETROVIRAL DRUGS 80
6.5.1 MINIMAL SIDE EFFECTS DUE TO TARGETED APPROACH TO SUPPORT MARKET GROWTH 80
TABLE 27 PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY REGION, 2021–2028 (USD MILLION) 80
TABLE 28 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 29 EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 30 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 81

6.6 OTHER THERAPEUTIC PRODUCTS 82
TABLE 31 PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 82
TABLE 32 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 33 EUROPE: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 34 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 83
7 PRECISION MEDICINE MARKET, BY INDICATION 84
7.1 INTRODUCTION 85
TABLE 35 PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 85
7.2 ONCOLOGY 85
7.2.1 INCREASING PRODUCT APPROVALS FOR CANCER THERAPEUTICS TO DRIVE MARKET 85
TABLE 36 PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 37 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 38 EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 39 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 87
7.3 RARE DISEASES 88
7.3.1 GROWING FOCUS ON PRODUCT DEVELOPMENT TO DRIVE MARKET 88
TABLE 40 PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 41 NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 42 EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 43 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 89
7.4 INFECTIOUS DISEASES 90
7.4.1 RISING INCIDENCE OF HIV AND TB TO FUEL MARKET 90
TABLE 44 PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 90
TABLE 45 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 46 EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 47 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 91

7.5 HEMATOLOGICAL DISORDERS 91
7.5.1 INCREASING CASES OF SICKLE CELL DISEASE AND ANEMIA TO SUPPORT MARKET GROWTH 91
TABLE 48 PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 92
TABLE 49 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 50 EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 51 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 93
7.6 OTHER INDICATIONS 93
TABLE 52 PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 53 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 54 EUROPE: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 55 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 95
8 PRECISION MEDICINE MARKET, BY END USER 96
8.1 INTRODUCTION 97
TABLE 56 PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 97
8.2 HOSPITALS AND CLINICS 97
8.2.1 WIDE ADOPTION OF PRECISION MEDICINE FOR COMPLEX MEDICAL PROCEDURES TO DRIVE MARKET 97
TABLE 57 PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 58 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 59 EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 60 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 99
8.3 HOME CARE SETTINGS 100
8.3.1 ADVANTAGES OF PATIENT COMFORT AND REDUCED HOSPITAL STAYS TO SUPPORT MARKET GROWTH 100
TABLE 61 PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 62 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 63 EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 64 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 101

9 PRECISION MEDICINE MARKET, BY REGION 102
9.1 INTRODUCTION 103
TABLE 65 PRECISION MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION) 103
9.2 NORTH AMERICA 103
FIGURE 26 NORTH AMERICA: PRECISION MEDICINE MARKET SNAPSHOT 104
TABLE 66 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 67 NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 105
TABLE 68 NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 105
TABLE 69 NORTH AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 106
9.2.1 US 106
9.2.1.1 Rising regulatory approvals for therapeutic products to drive market 106
TABLE 70 PERSONALIZED MEDICINE PRODUCT APPROVALS BY US FDA 106
TABLE 71 US: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
TABLE 72 US: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 107
TABLE 73 US: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 108
9.2.2 CANADA 108
9.2.2.1 Rising incidence of cancer to drive market 108
TABLE 74 CANADA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 75 CANADA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 109
TABLE 76 CANADA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.2.3 NORTH AMERICA: RECESSION IMPACT 109
9.3 EUROPE 110
FIGURE 27 EUROPE: PRECISION MEDICINE MARKET SNAPSHOT 111
TABLE 77 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 78 EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 79 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 113
TABLE 80 EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.3.1 GERMANY 113
9.3.1.1 Rising R&D initiatives for therapeutics to drive market 113
TABLE 81 GERMANY: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 114

TABLE 82 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 114
TABLE 83 GERMANY: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 115
9.3.2 UK 115
9.3.2.1 Rising incidence of hematologic cancers to drive market 115
TABLE 84 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 115
TABLE 85 UK: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 116
TABLE 86 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 116
TABLE 87 UK: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 117
9.3.3 FRANCE 117
9.3.3.1 Increasing initiatives in genomic research to drive market 117
TABLE 88 FRANCE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 89 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 118
TABLE 90 FRANCE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 118
9.3.4 ITALY 118
9.3.4.1 Growing awareness initiatives for personalized treatment to propel market 118
TABLE 91 ITALY: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 92 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 119
TABLE 93 ITALY: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 120
9.3.5 SPAIN 120
9.3.5.1 Rising funding initiatives for cell and gene therapies to support market growth 120
TABLE 94 SPAIN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 95 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 121
TABLE 96 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 121
9.3.6 REST OF EUROPE 121
TABLE 97 REST OF EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 98 REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 122
TABLE 99 REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 123
9.3.7 EUROPE: RECESSION IMPACT 123

9.4 ASIA PACIFIC 123
TABLE 100 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 101 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 102 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 125
TABLE 103 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 125
9.4.1 CHINA 125
9.4.1.1 High incidence of chronic diseases and large patient volume to fuel market 125
TABLE 104 CHINA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 105 CHINA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 126
TABLE 106 CHINA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 127
9.4.2 JAPAN 127
9.4.2.1 Availability of reimbursements for medical procedures to support market growth 127
TABLE 107 JAPAN: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 108 JAPAN: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 128
TABLE 109 JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 129
9.4.3 INDIA 129
9.4.3.1 Rising burden of chronic diseases to drive market 129
TABLE 110 INDIA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 111 INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 130
TABLE 112 INDIA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 131
9.4.4 AUSTRALIA 131
9.4.4.1 Rising R&D projects for genomic sequencing to propel market 131
TABLE 113 AUSTRALIA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 114 AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 132
TABLE 115 AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 132
9.4.5 REST OF ASIA PACIFIC 132
TABLE 116 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 117 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 133

TABLE 118 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 134
9.4.6 ASIA PACIFIC: RECESSION IMPACT 134
9.5 LATIN AMERICA 134
9.5.1 INVESTMENTS IN PRECISION MEDICINE DIAGNOSTICS TO SUPPORT MARKET GROWTH 134
TABLE 119 LATIN AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 120 LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 135
TABLE 121 LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 136
9.5.2 LATIN AMERICA: RECESSION IMPACT 136
9.6 MIDDLE EAST 136
9.6.1 RISING AWARENESS OF INNOVATIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH 136
TABLE 122 MIDDLE EAST: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 123 MIDDLE EAST: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 137
TABLE 124 MIDDLE EAST: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 138
9.7 AFRICA 138
9.7.1 INCREASING COLLABORATIVE EFFORTS WITH ESTABLISHED COUNTRIES FOR PRECISION DIAGNOSTICS TO SUPPORT MARKET GROWTH 138
TABLE 125 AFRICA: PRECISION MEDICINE MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 126 AFRICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021–2028 (USD MILLION) 139
TABLE 127 AFRICA: PRECISION MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION) 139
9.8 MIDDLE EAST & AFRICA: RECESSION IMPACT 139
10 COMPETITIVE LANDSCAPE 140
10.1 OVERVIEW 140
10.1.1 STRATEGIES ADOPTED BY KEY PLAYERS 141
10.2 MARKET SHARE ANALYSIS 142
FIGURE 28 PRECISION MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 142
TABLE 128 PRECISION MEDICINE MARKET: INTENSITY OF COMPETITIVE RIVALRY 142
10.3 REVENUE SHARE ANALYSIS 143
FIGURE 29 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2020−2022) 143
10.4 COMPANY EVALUATION MATRIX 144
FIGURE 30 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (2022) 144
10.4.1 STARS 145
10.4.2 PERVASIVE PLAYERS 145
10.4.3 EMERGING LEADERS 145
10.4.4 PARTICIPANTS 145
10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES 146
FIGURE 31 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 146
10.5.1 PROGRESSIVE COMPANIES 147
10.5.2 STARTING BLOCKS 147
10.5.3 DYNAMIC COMPANIES 147
10.5.4 RESPONSIVE COMPANIES 147
10.6 COMPETITIVE BENCHMARKING OF LEADING PLAYERS 147
10.6.1 PRODUCT FOOTPRINT OF COMPANIES 147
TABLE 129 PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS 147
10.6.2 REGIONAL FOOTPRINT OF COMPANIES 149
TABLE 130 PRECISION MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS 149
10.7 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 150
TABLE 131 PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES 150
TABLE 132 PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 151
10.8 COMPETITIVE SCENARIO AND TRENDS 151
10.8.1 PRODUCT APPROVALS 151
TABLE 133 PRECISION MEDICINE MARKET: PRODUCT APPROVALS (JANUARY 2020−JUNE 2023) 151
10.8.2 DEALS 152
TABLE 134 PRECISION MEDICINE MARKET: DEALS (JANUARY 2020−JUNE 2023) 152
10.8.3 OTHER DEVELOPMENTS 153
TABLE 135 PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS (JANUARY 2020−JULY 2023) 153
11 COMPANY PROFILES 154
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 KEY PLAYERS 154
11.1.1 F. HOFFMANN-LA ROCHE LTD. 154
TABLE 136 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 154
FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 155
TABLE 137 F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS 157
11.1.2 BRISTOL MYERS SQUIBB 159
TABLE 138 BRISTOL MYERS SQUIBB: COMPANY OVERVIEW 159
FIGURE 33 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2022) 160
TABLE 139 BRISTOL MYERS SQUIBB: DEALS 161
TABLE 140 BRISTOL MYERS SQUIBB: PRODUCT APPROVALS 161
11.1.3 NOVARTIS AG 164
TABLE 141 NOVARTIS AG: COMPANY OVERVIEW 164
FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2022) 165
TABLE 142 NOVARTIS AG: DEALS 168
TABLE 143 NOVARTIS AG: PRODUCT APPROVALS 169
11.1.4 GILEAD SCIENCES, INC. 171
TABLE 144 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 171
FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022) 172
TABLE 145 GILEAD SCIENCES, INC.: DEALS 173
TABLE 146 GILEAD SCIENCES, INC.: PRODUCT APPROVALS 174
11.1.5 ASTRAZENECA 175
TABLE 147 ASTRAZENECA: COMPANY OVERVIEW 175
FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2022) 175
TABLE 148 ASTRAZENECA: DEALS 176
TABLE 149 ASTRAZENECA: PRODUCT APPROVALS 177
11.1.6 ABBVIE INC. 178
TABLE 150 ABBVIE INC.: COMPANY OVERVIEW 178
FIGURE 37 ABBVIE INC.: COMPANY SNAPSHOT (2022) 179
TABLE 151 ABBVIE INC.: DEALS 180
11.1.7 ELI LILLY AND COMPANY 181
TABLE 152 ELI LILLY AND COMPANY: COMPANY OVERVIEW 181
FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022) 182
TABLE 153 ELI LILLY AND COMPANY: DEALS 183
TABLE 154 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS 183
11.1.8 SAREPTA THERAPEUTICS, INC. 185
TABLE 155 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 185
FIGURE 39 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022) 185
TABLE 156 SAREPTA THERAPEUTICS, INC.: DEALS 186
TABLE 157 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS 186
TABLE 158 SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS 187
11.1.9 PFIZER INC. 188
TABLE 159 PFIZER INC.: COMPANY OVERVIEW 188
FIGURE 40 PFIZER INC.: COMPANY SNAPSHOT (2022) 189
TABLE 160 PFIZER INC.: DEALS 190
TABLE 161 PFIZER INC.: PRODUCT APPROVALS 191
TABLE 162 PFIZER INC.: OTHER DEVELOPMENTS 191
11.1.10 GLAXOSMITHKLINE PLC 192
TABLE 163 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW 192
FIGURE 41 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022) 193
TABLE 164 GLAXOSMITHKLINE PLC: DEALS 195
TABLE 165 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS 195
11.1.11 SANOFI 197
TABLE 166 SANOFI: COMPANY OVERVIEW 197
FIGURE 42 SANOFI: COMPANY SNAPSHOT (2022) 198
TABLE 167 SANOFI: DEALS 199
TABLE 168 SANOFI: PRODUCT APPROVALS 200
11.1.12 JOHNSON & JOHNSON 202
TABLE 169 JOHNSON & JOHNSON: COMPANY OVERVIEW 202
FIGURE 43 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022) 203
TABLE 170 JOHNSON & JOHNSON: PRODUCT APPROVALS 204
11.1.13 BLUEBIRD BIO, INC. 205
TABLE 171 BLUEBIRD BIO, INC.: COMPANY OVERVIEW 205
FIGURE 44 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022) 205
TABLE 172 BLUEBIRD BIO, INC.: PRODUCT LAUNCHES 206
TABLE 173 BLUEBIRD BIO, INC.: PRODUCT APPROVALS 206
11.1.14 MERCK KGAA 208
TABLE 174 MERCK KGAA: COMPANY OVERVIEW 208
FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022) 209
TABLE 175 MERCK KGAA: PRODUCT APPROVALS 210
11.1.15 AMGEN, INC. 211
TABLE 176 AMGEN, INC.: COMPANY OVERVIEW 211
FIGURE 46 AMGEN, INC.: COMPANY SNAPSHOT (2022) 212
TABLE 177 AMGEN, INC.: DEALS 213
TABLE 178 AMGEN, INC.: PRODUCT APPROVALS 213
11.1.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED 214
TABLE 179 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW 214
FIGURE 47 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022) 215
TABLE 180 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS 216
11.1.17 REGENERON PHARMACEUTICALS, INC. 217
TABLE 181 REGENERON PHARMACEUTICALS, INC.: COMPANY OVERVIEW 217
FIGURE 48 REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022) 217
TABLE 182 REGENERON PHARMACEUTICALS, INC.: DEALS 218
TABLE 183 REGENERON PHARMACEUTICALS, INC.: PRODUCT APPROVALS 218
11.1.18 IMMUNOCORE LTD. 219
TABLE 184 IMMUNOCORE LTD.: COMPANY OVERVIEW 219
FIGURE 49 IMMUNOCORE LTD.: COMPANY SNAPSHOT (2022) 220
TABLE 185 IMMUNOCORE LTD.: DEALS 221
TABLE 186 IMMUNOCORE LTD.: PRODUCT APPROVALS 221
11.1.19 BLUEPRINT MEDICINES CORPORATION 222
TABLE 187 BLUEPRINT MEDICINES CORPORATION: COMPANY OVERVIEW 222
FIGURE 50 BLUEPRINT MEDICINE: COMPANY SNAPSHOT (2022) 222
TABLE 188 BLUEPRINT MEDICINES CORPORATION: DEALS 223
TABLE 189 BLUEPRINT MEDICINES CORPORATION: PRODUCT APPROVALS 224
11.2 OTHER PLAYERS 225
11.2.1 VERTEX PHARMACEUTICALS INCORPORATED 225
11.2.2 MIRATI THERAPEUTICS, INC 226
11.2.3 ARGENX SE 226
11.2.4 HORIZON THERAPEUTICS PLC 227
11.2.5 BRIDGEBIO PHARMA, INC. 227
11.2.6 TREVENA, INC. 228
11.2.7 INCYTE CORPORATION 228
11.2.8 ALNYLAM PHARMACEUTICALS, INC. 229
11.2.9 RIGEL PHARMACEUTICALS, INC. 229
11.2.10 TAIHO PHARMACEUTICAL CO., LTD (PART OF OTSUKA HOLDINGS CO., LTD.) 230
11.2.11 AGIOS PHARMACEUTICALS, INC. 230
11.2.12 SEAGEN, INC. 231
11.2.13 RHYTHM PHARMACEUTICALS, INC. 231
11.2.14 MACROGENICS, INC. 232
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX 233
12.1 DISCUSSION GUIDE 233
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 237
12.3 CUSTOMIZATION OPTIONS 239
12.4 RELATED REPORTS 239
12.5 AUTHOR DETAILS 240

ページTOPに戻る

Table of Contents

Summary

The precision medicine market is expected to reach USD 50.2 billion by 2028 from USD 29.1 billion in 2023, at a CAGR of 11.5% during the forecast period. The key factors driving the growth of the precision medicine market include growing initiatives related to genomic research, and increasing number of regulatory approvals for personalized therapeutics. Moreover, rising demand for cell and gene therapies is an opportunity area for this market.
The precision medicine market has been segmented based on type, indication, end user and region.
“By type, the monoclonal antibodies segment accounted for the second largest share of the precision medicine market”
Based on type, the precision medicine market is categorized into inhibitor drugs, monoclonal, cell & gene therapy, antiviral & antiretroviral drugs, and other therapeutic products. In 2022, monoclonal antibodies accounted for the highest growth rate owing to factors such as benefits offered by monoclonal antibodies over traditional medicines. These advantages have led to shifting focus of the clinical pipeline dominantly on monoclonal antibodies.
“By end user, the hospitals and clinics segment accounted for the largest share in the precision medicine market”
Based on end user, the precision medicine market is segmented into hospitals and clinics and home care settings. In 2022, the hospitals and clinics segment accounted for a largest share of the precision medicine market. Growth in this market segment can be attributed to availability of services such as genetic testing, diagnostics and counselling in hospital setups. Besides, hospitals have easy accessibility of therapeutic products which are made available for patients opting for precison medicine regime.

“North America: the largest share of the precision medicine market”
North America accounted for the largest share of the precision medicine market. The large share of the North America region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering precision medicines, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market.
“Europe: The fastest-growing region in the precision medicine market.”
The Europe precision medicine market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for precision medicine advancements with presence of some of the key players in the market. Some examples of these players include F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), AstraZeneca (UK), GlaxoSmithKline plc (UK) among others.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
• By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 2.5% & Africa- 2.5%

Prominent Players
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Novartis AG (Switzerland)
• Pfizer Inc. (US)
• Bristol Myers Squibb (US)
• AstraZeneca (UK)
• Gilead Sciences, Inc. (US)
• AbbVie Inc. (US)
• Eli Lilly and Company (US)
• GlaxoSmithKline plc (UK)
• Sanofi (France)
• Johnson & Johnson (US)
• Merck KGaA (Germany)
• Amgen, Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• Regeneron Pharmaceuticals, Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• bluebird bio, Inc. (US)
• Immunocore Holdings Plc (UK)
• Blueprint Medicines Corporation (US)
• Vertex Pharmaceuticals Incorporated (US)
• Horizon Therapeutics Plc (Ireland)
• Alnylam Pharmaceuticals, Inc. (US)
• Rigel Pharmaceuticals, Inc. (US)
• Taiho Pharmaceutical Co., Ltd. (Japan)
• Seagen Inc. (US)
Research Coverage:
This report provides a detailed picture of the precision medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the precision medicine market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
• Analysis of key drivers (growth in genomic research, genetic testing and companion diagnostics), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with precision medicines adoption) influencing the growth of the precision medicine market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the precision medicine market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the precision medicine market across varied regions.
• Market Diversification: Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the precision medicine market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Bristol Myers Squibb (US), Gilead Sciences, Inc. (US), AstraZeneca (UK), Pfizer Inc. (US), AbbVie Inc. (US), Eli Lilly and Company (US), , GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson (US), Merck KGaA (Germany), Amgen, Inc. (US), Takeda Pharmaceutical Company Limited (Japan) among others in the precision medicine market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（antibodies）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（antibodies）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?